Mar. 20 at 11:42 AM
$INMB $INMB 🔬 Big momentum building here — Lucid Capital just upgraded INmune Bio to Buy with a
$9 price target (from
$2) on March 11 🚀 That’s a major vote of confidence in the pipeline, especially its neuroinflammation/Alzheimer’s program. At ~
$1.30 levels, this looks like an early-stage opportunity before broader market attention kicks in. With upcoming catalysts and growing analyst support, INMB has serious upside potential if execution stays on track. 📈
$DNUT $OPEN $GME
